Please login to the form below

Not currently logged in

TxCell plans listing as EU biotech wakes up to IPOs

Move follows UK allergy therapy developer Circassia's listing

The return of the biotech initial public offering (IPO) in 2013 was largely a US phenomenon, but France's TxCell is flying the flag for Europe with a decision to list on NYSE Euronext.

The Valbonne-based specialist in personalised cell therapies announced its intention to float at the same time as it unveiled a €76m ($108m) deal giving Ferring Pharmaceuticals an exclusive option to license worldwide rights to its lead candidate Ovasave for ulcerative colitis and Crohn's disease.

TxCell's move comes shortly after UK allergy therapy developer Circassia raised £200m ($333m) via an IPO on the London Stock Exchange and raises the prospect of other European biotechs going it alone rather than partnering with larger pharma companies at an early stage.

Reuters suggests three other European biotechs - AC Immune, Novimmune and Molecular Partners - are also thinking about going public at the moment, indicating rising confidence among the investment community about the prospects for Europe's sector.

There were 23 biotech IPOs in the US last year, rising from 13 a year earlier and well ahead of the low single-digit levels seen when the global economy first took a dive in 2008, according to an analysis in BiotechNOW. Over the same period there have only been a handful of EU listings each year.

TXCell's technology platform is based on the use of antigen-specific regulatory T cells - known as 'Tregs' - and the company is due to start a phase 2b trial of Ovasave later this year in patients with refractory Crohn's disease.

The Tregs are made by harvesting blood from a patient, stimulating T cells to respond to a particular antigen and expanding their population to provide enough material to treat a patient over multiple years.

Ferring is paying €3m upfront for rights to Ovasave, and will be responsible for funding and carrying out development of the therapy after TxCell completes the phase 2b trial. It is estimated that around 100,000 Crohn's disease patients in the US and Europe are refractory to current treatment.

Article by
Phil Taylor

19th March 2014

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...